Exondys 51
Named-patient access overview. Exondys 51 is coordinated by Reserve Meds for international patients via physician-led cross-border sourcing.
Quick orientation
Exondys 51 (eteplirsen) is Sarepta's exon 51-skipping antisense oligonucleotide for Duchenne muscular dystrophy. It received FDA accelerated approval in 2016 for the approximately 13 percent of DMD patients whose dystrophin gene mutation is amenable to exon 51 skipping. For Saudi Arabia families with a child who carries a confirmed exon 51-amenable DMD mutation, this page describes the SFDA Personal Importation Program pathway.
Case active and ready to skip the regulatory walkthrough? Start your case or WhatsApp us.
How Reserve Meds coordinates Exondys 51
- Patient or treating physician submits an intake at the patient portal.
- Reserve Meds clinical team verifies appropriateness for the patient and destination country.
- Treating physician issues prescription and clinical justification.
- Country-specific named-patient documentation is prepared.
- Exondys 51 is sourced from a DSCSA-compliant US specialty wholesaler with full serial traceability.
- Shipment is coordinated to the patient's physician or hospital pharmacy with appropriate handling.
Access by country
Reserve Meds publishes a detailed country deep-dive for Exondys 51 in every market we coordinate. Each page below covers the destination-country regulatory pathway, real costs, indicative timelines, physician-credential requirements, and handling notes. Tap any country to read the full deep-dive.
Start a request for Exondys 51
Submit a 60-second intake. The clinical team will follow up within 24 hours with case-specific feasibility, timeline, and a formal quote.